Decheng Capital buys 1,250,000 shares in AARD for $20,000,000.00 (2 transactions at $16.00 blended avg) amid cluster buy pattern
Decheng Capital Global Life Sciences Fund IV, L.P., a 10% owner of Aardvark Therapeutics, executed 2 separate purchases totaling 1,250,000 shares for $20,000,000.00 at a blended average price of $16.00 on 2025-02-14. The transaction increases the fund's shareholding to 958,412 shares post-transaction, reflecting a net addition of 1,250,000 shares. This purchase coincides with a broader cluster of insider buying activity: 3 other insiders have also bought within the past 14 days. The stock is trading at $14.90 as of 2025-02-19 (4 trading days post-transaction), suggesting the current market price has moved below the transaction price. The derivative-conversion flag indicates this filer holds additional economic interests in Form 4 Table II not yet populated in the database, so the post-transaction tally of 958,412 shares does not represent the insider's full position.